Stabilized formulations containing Anti-CD20 x Anti-CD3 bispecific antibodies

MYPI2025004341A0Undetermined Publication Date: 2021-06-10REGENERON PHARMACEUTICALS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2025004341
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-12-09
Filing Date
2020-12-09
Publication Date
2021-06-10
Patent Text Reader

Abstract

The present invention provides stable liquid pharmaceutical formulations comprising a human bispecific antibody that specifically binds to human CD20 and human CD3. In certain embodiments, the formulations contain, in addition to the bispecific antibody, a buffer, a surfactant, and a sugar. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability upon stress and storage.
Need to check novelty before this filing date? Find Prior Art